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October: This is one of the 
peculiarly dangerous months in 
which to speculate in stocks. 
The others are July, January, 
September, April, November, 
May, March, June, December, 
August and February. 
Mark Twain 
Well, I'm sure there is going to be 
speculation this month on more than 
just stocks! 
As you know, the detail work for our 
impending merger with Muhlenberg 
Hospital Center has begun. Due to 
certain quirks in Medicare law, there is 
a significant fiscal advantage to the 
new Lehigh Valley Health Network if 
the merger is consummated by 
November 30. In general, Lehigh 
Valley Health Network will be the 
parent organization and have a Board 
of Trustees of 25 members, the 20 
members currently sitting on the 
Board of Lehigh Valley Hospital and 
an additional five representatives from 
the current Muhlenberg Hospital 
Center Board. Each hospital will keep 
its own Board, the responsibilities of 
which will focus around issues such as 
credentialing. As I mentioned in last 
months Medical Staff Progress Notes, 
each hospital will also maintain its 
own medical staff during the initial 
phase of the merger. The Medical 
Staff Transition Task Force 
representing Lehigh Valley Hospital 
consists of David M. Caccese, MD, 
your President-Elect; Robert J. 
Laskowski, MD, the Chief Medical 
Officer of Lehigh Valley Health 
Network; Herbert C. Hoover, Jr., MD, 
Chairperson, Department of Surgery; 
John P. Fitzgibbons, MD, 
Chairperson, Department ofMedicine; 
John W. Hart, Vice President, and 
myself. Members from Muhlenberg 
Hospital Center include John Lang, 
DO, President, Medical Staff; Hugo 
Twaddle, MD, Past President, Medical 
Staff; Marc Granson, MD, Chief of 
Surgery; Gavin Barr, MD, Vice 
President/Medical Director, and Vince 
Tallarico, Vice President, Business 
Development/Physician Services. I 
am sure we will be soliciting the 
opinions and participation of many of 
you in the weeks to come. Of course, 
you should always feel free to voice 
your concerns to us at any time. 
Another very important issue facing 
the Medical Staff this month is the site 
visit by inspectors for the Joint 
Commission on Accreditation of 
Hospital Organizations. While no date 
has been announced as yet, we 
anticipate these inspectors will be here 
(Continued on Page 2) 
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for five days sometime during this 
month. 1997 will mark the first year 
that inspections will include 
interviews with physicians and other 
hospital personnel selected at random, 
not just Department Chairs and Heads. 
For those of you who attended the 
Quarterly Meeting of the Medical 
Staff in September, hopefully, you 
were able to develop a sense of what 
these interviews might involve. You 
were also supplied with some "cheat 
sheets" to carry in your pocket for 
easy reference if you should be 
selected by an interviewer. For those 
of you who were unable to attend that 
meeting, I encourage you all to drop 
by the Medical Staff Services office to 
pick up these reference materials. 
Speaking of the Quarterly Meeting of 
the Medical Staff, currently, these 
meetings are scheduled to begin at 
5:30p.m. However, it has become 
obvious to me that it is difficult to 
obtain a quorum until later in the 
evenipg. Accordingly, from this point 
forward, we will begin our Quarterly 
Meetings at 5:45p.m. 
October will also be the first full 
month of construction on our new $52 
million East Wing building. The 
groundbreaking ceremony, which took 
place on Monday, September 8, began 
yet another chapter in Lehigh Valley 
Hospital's commitment to provide its 
community, patients, and physicians 
with the finest facilities available. We 
look forward to the anticipated ribbon 
cutting ceremony in January 2000! 
I'd like to congratulate Raymond L. 
Singer, MD, on his recent election to 
the Medical Executive Committee, the 
highest governing committee of the 
Medical Staff. Ray will be filling the 
vacancy caused by the resignation of 
John Samies, :MD. While we certainJ 
miss John, we all look forward to 
working with Ray on the first Tuesday 
evening of each month. 
This month, the Medical Executive 
Committee will get back to work and 
resume its discussions on 
physician/hospital alignment issues. 
These might include additional issues 
raised in light of the impending 
merger with Muhlenberg Hospital 
Center. As always, please feel free to 
bring your concerns to any member of 
the Medical Executive Committee or 
Troika to help facilitate our 
discussions. 
I hope you all survive the return of 
Standard Time! 
Robert X. Murphy, Jr., MD 
President, Medical Staff 
On October 1, certified letters were 
mailed to those physicians who have 
not yet paid their Medical Staff dues. 
In order to avoid automatic 
resignation from the Medical Staff as 
mandated by the Bylaws, please 
forward your check payable to 
Medical Staff of Lehigh Valley 
Hospital before October 15, 1997, to 
Janet M. Seifert, Medical Staff 
Services, Lehigh Valley Hospital, 
Cedar Crest & 1·78, P.O. Box 689, 
Allentown, PA 18105-1556. 
If you have any questions regarding 
your dues, please contact Mrs. 
Seifert at 402-8590. I 
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L VH-MHC Merger Talks Continue 
Now that the decision to merge has 
been announced, the work of creating 
a single organization of Lehigh 
Valley Hospital (L VH) and 
Muhlenberg Hospital Center (MHC) 
has begun. 
Two transition teams have been 
created with members from both 
institutions to lead the process of 
integration, according to Lou 
Liebhaber, L VH chief operating 
officer. 
The senior oversight group will guide 
major policy and programmatic 
decisions related to the transition. 
Members of the group include: 
From LVH 
Elliot J. Sussman, MD, President and 
CEO 
Robert J. Laskowski, MD, Senior Vice 
President, Clinical Services 
Louis L. Liebhaber, Chief Operating 
Officer 
FromMHC 
William R. Mason, President and 
CEO 
Gavin Barr, MD, Vice President, 
Medical Director 
Ronald Macaulay, Vice President, 
Finance 
The operations transition team will be 
responsible for the integration, 
planning and implementation of all 
merger issues, except clinical 
programs unless directed by the 
oversight group and physician issues. 
Members of the team include: 
FromLVH 
Louis Liebhaber, Chief Operating Officer (Chair) 
Vaughn Gower, Chief Financial Officer 
Harry Lukens, Chief Information Officer 
Mary Kinneman, Senior Vice President, Patient 
Care Services 
MaryKay Gooch, Vice President, Human 
Resources 
Mary Alice Czerwonka, Vice President Public 
Affairs 
Stuart Paxton, VICe President Consumables 
Management 
James Burke, Vice President, Operations 
John Hart, Vice President Medical Staff Services 
FromMHC 
Ronald Macaulay, Vice President Finance 
Jonathan Brenn, Chief Operating Officer 
Christopher Callahan, Director, Human Resources 
Terry Capuano, Vice President Patient Care 
Melissa Wright, Director, Community Relations 
Louis Bottitta, Director, Information Services 
Vincent Tallarico, Vice President Business 
Development/Physician Services 
Charles Fenstermaker, Assistant Vice President 
Operations 
David Dylewski, Director, Mental Health 
Beginning in September, the groups 
began meeting regularly to identify 
issues and needs, and create 
implementation plans. Additional 
teams will be formed as needed. 
Special, routine communication 
mechanisms are being developed to 
keep employees at both L VH and 
MHC informed, and to provide 
opportunities for input and feedback. 
In the meantime, employees are 
encouraged to ask questions and raise 
issues with any member of the 
transition teams. 
"As our relationship has been over the 
past three years, so will the transition 
go," Mr. Liebhaber said. "We have a 
history of working together as 
partners, of mutual respect, trust and 
admiration, and that will continue as 
we merge our efforts to care for the 
Lehigh Valley." 
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Completion of Medical Records 
The need for timely completion of medical 
records is necessary for patient care and 
appropriate reimbursement to the 
institution. 
According to Medical Staff Bylaws, a 
complete history and physical 
examination shall, in all cases, be dictated 
or documented in the medical record no 
later than 24 hours after admission of the 
patient. For elective or outpatient 
procedures, preadmission history and 
physical examinations must be performed 
by a credentialed member of the Medical, 
Allied Health, or Residency staff within 30 
days prior to admission. 
Prior to surgery, all patients shall have a 
surgical consultation or pre-operative note 
completed. Operative reports are dictated 
or written in the medical record 
immediately after surgery. 
Any outpatient surgery report dictated by a 
physician and written by a nurse must be 
signed by the physician. A physician's 
signature validates the instructions as if he 
or she had written the operative note 
himself or herself. Lack of a physician's 
signature will result in a chart deficiency. 
Timely completion of the medical record 
within 30 days is a requirement of the Joint 
Commission for Accreditation of Health 
Care Organizations (JCAHO). The resident 
will have a total of 10 days to complete the 
discharge summary, in compliance with the 
rules and regulations of the residency 
program. The attending physician will have 
an additional IS days to complete the 
charts, after which time the attending 
physician will be held responsible, and his 
or her admitting, consultation and operating 
privileges will be suspended. Records 
devoid of an acceptable History/Physical 
exam or operative dictation at the time of 
discharge, must have these reports dictated 
within 24 hours or the attending will be held 
responsible. Discharge Summaries are to be 
dictated by the attending physician at the 
time or discharge. 
In accordance with Medical Staff Bylaws, a 
temporary suspension of an individual 
physician/group in the form ofwithdrawal 
of all admitting, consultation, treatment and 
surgical privileges shall be imposed 
automatically after warning of a 
delinquency. A written warning of a 
delinquency shall occur one week prior to 
suspension for failure to complete medical 
records. 
Courtesy Telephone Calls to Cease 
For many years, in addition to the written 
warning of delinquency sent to physicians the 
week prior to suspension, COURTESY phone 
calls have been made by the Medical Record 
Department to the physicians' offices on 
Tuesdays (the day prior to suspension), and 
by the staff of Medical Staff Services on 
Wednesdays (the day of suspension). As 
these phone calls take up a significant 
amount of staff time in both departments, and 
since there has been a dramatic decrease in ) 
the number of delinquent charts in Medical 
Records, a change to this procedure was 
recommended to and supported by the 
Medical Executive Committee at its 
September meeting. 
Therefore, beginning November 1, 1997, 
COURTESY telephone calls will be reduced. 
After that date, COURTESY reminder phone 
calls to physicians will be made only on 
Tuesdays by the Medical Record Department. 
Effective January 1, 1998, COURTESY 
reminder phone calls will cease completely. 
Beginning on January 1, faxes will be sent to 
physicians' offices stating that records are 
delinquent. It will then be the responsibility of 
the offices to contact the Medical Record 
Department to obtain information regarding 
the delinquent records. 
If you have any questions regarding this 
issue, please contact Zelda Greene, Director 








Notice/Waiver in Response to 
New Medicare Requirements 
Health Network Laboratories has 
revised its clinical laboratory requisition 
form to facilitate our compliance with 
Medicare. The purpose of this article is 
to explain these changes to you, to let 
you know what Health Network 
Laboratories is doing in response, and 
to solicit your help in meeting the 
needs of your patients as effectively and 
efficiently as possible. A letter which 
explains this information will also be 
mailed to each physician's office. 
Xact Medical Services and V eritus, 
carriers for Medicare, distributed 
Special Notices highlighting the 
Diagnosis Reporting Requirements for 
Clinical Laboratory Services. This 
notice specifies that diagnosis codes 
are required for all laboratory tests. 
In addition, special requirements have 
been put in place for Medicare patients 
pertaining to certain tests to determine 
the medical necessity of the test(s). If 
the diagnoses do not meet the Medicare 
reimbursement rules, payment will be 
denied. Also, payment will be denied 
for tests currently designated as 
research use only. In these cases, we 
can only seek reimbursement from the 
patient if they have been notified in 
advance of the testing that Medicare is 
likely to deny payment and, if they have 
signed an Advanced Beneficiary 
Notice/Waiver. The Advanced 
Beneficiary Notice/ Waiver should only 
be used when it is believed that 
Medicare is likely to deny payment for 
a particular test because it is not 
reasonable and necessary for the 
reported diagnosis, it 
is a research use only test, or it is a 
routine screening test. 
These policies do, regrettably, 
necessitate Health Network 
Laboratories to require the following 
from you: 
• Complete diagnosis information on 
all prescriptions and requisitions 
for laboratory testing (Medicare, 
patient billing, or any 
commercial insurance carrier). 
The diagnosis in ICD-9 format is 
preferred, and as many diagnoses 
or symptoms as applicable should 
be provided. 
If specimens are collected in your 
office and sent to Health Network 
Laboratories for testing, the following 
is also required, when applicable: 
• Medicare patients must be asked 
to sign the Advanced Beneficiary 
Notice on the Health Network 
Laboratories LAB-50 Requisition 
Form, when applicable. Refer to 
"Advanced Beneficiary Notice -
Medicare Patient Information 
Sheet" included in the information 
packet mailed to your office for 
details. 
• If a patient refuses to sign the 
Advanced Beneficiary Notice but 
demands the service, you should 
have a second person witness that 
the patient was given the notice but 
refused to sign; both you and the 
witness should attest to this in 
writing on the Advanced 
Beneficiary Notice, including your 
signatures and the date. 
If specimens are collected at one of the 
Health Network Laboratories outpatient 
laboratories, our staff will ask the 
Medicare patient to sign the Advanced 
Beneficiary Notice, when applicable. 
(Continued on Page 10) 
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With your assistance in providing all 
the relevant information on the initial 
test requisition form, there should be no 
need for follow-up telephone calls or 
correspondence, thus saving valuable 
time for both you, your staff, and our 
laboratory personnel. 
Health Network Laboratories is making 
every effort to help you provide the 
information necessary to assure 
satisfactory resolution of the billing 
process. The laboratory staff will work 
with you to keep the process as simple 
and efficient as possible. Updates to the 
test listing will be provided to you as 
they are received from Medicare. 
The staff of Health Network 
Laboratories looks forward to working 
with you to implement the changing 
policies. We welcome suggestions that 
you or your office staff may have to 
make this process easier while 
preserving the compliance 
requirements. Your cooperation is 
greatly appreciated in including ICD-9 
diagnosis codes on all tests ordered and 
having patients sign the Advanced 
Beneficiary Notice. We sincerely regret 
any inconvenience these new 
requirements may cause you or your 
patients. If you have any questions, 
please contact Jan Gushen, Manager, 
Client Services, at 402-4436; Lisa 
Anthony, Coordinator, Client Services, 
at 402-5658; David Beckwith, PhD, 
Vice President, Network Laboratory 
Services and Clinical Director, Health 
Network Laboratories, at 402-8150; or 
John J. Shane, MD, Chairperson, 
Department of Pathology, at 402-8141. 
New Lot of Thromboplastin Reagent 
As of September 17, the Health 
Network Laboratories will be using a 
new lot of thromboplastin reagent that 
is used for activated partial 
thromboplastin times (APTT). In 
patients receiving heparin therapy, the 
APTT therapeutic range in seconds for 
the new thromboplastin being used as of 
September 17 is 43-70 seconds. The 
43-70 seconds equals a plasma heparin 
level of0.2 to 0.4 units/cc. 
The new lot of the thromboplastin 
reagent will be used by Health Network 
Laboratories for about one year. The 
supplier of the partial thromboplastin 
reagent will make sure we receive the 
same lot for the next 12 months. 
Lab to Discontinue Enzymatic Acid 
Phosphatase 
Effective October 1, 1997, Health 
Network Laboratories will discontinue 
offering an enzymatic acid phosphatase 
through the Clinical Laboratory. 
Requisitions for enzymatic acid 
phosphatase will be reflexed to a 
prostatic acid phosphatase (PAP). PAP 
gives essentially the same information ) 
clinically with significantly better 
specificity. 
The lab has had inquiries concerning 
age-specific reference ranges for PSA 
(an issue that remains extremely 
controversial) and, at least for the 
moment, age-specific ranges will not be 
adopted but will continue with the 
current standard as normal for all age 
groups. 
If you have any questions regarding this 
issue, please contact John J. Shane, 
Chairperson, Department of Pathology, 
at 402-8141. 
When scheduling patients for hospital 
admission, tests, treatment or consultation, 
please inform the scheduler of latex allergic 
patients and the extent of the allergy, i.e., 
contact, respiratory or both. Advance 
notification is necessary to provide a latex· 




News from the Library 
OVID Training 
To schedule a one-on-one OVID 
(MEDLINE) 1raining session, please call 
Barbara Iobst in the Health Sciences 
Library at 402-8408. 
News from the National 
Library of Medicine 
Health consumers are applauding the 
National Library ofMedicine's 
announcement of July 26 that made 
MEDLINE, a database of more than 8.8 
million references to articles published in 
3,800 biomedical journals, free of charge 
to them on the World Wide Web. This 
will be accomplished by free access tO 
Internet Grateful Med and PubMed. 
World-Wide-Web access is readily 
available at public and academic libraries. 
The National Library of Medicine's Web 
address or URL is 
http://www.nlm.nih.gov/ 
••Health consumers are encouraged to 
discuss their MEDLINE search results 
with their health care provider." If you do 
not currently have Web access and would 
like to view this site and other 
government consumer health sites, stop 
by either location of the Health Sciences 
Library. 
Papers, Publications and Presentations 
George F. Carr, DMD, Division of 
Prosthodontics/Special Care, was an invited 
speaker at the International Congress of 
Oral Implantology annual meeting in 
Vancouver, British Columbia, Canada, held 
August 15-18. Dr. Carr's topic was 
R.A.P .I.D. (Repeatable and Predictable 
Implant Dentistry) Prosthodontics. He has 
been a Diplomat of the organization since 
1991 and has served on various committees 
for the I.C.O.I. throughout his membership 
since 1988. 
Ross N. Futerfas, MD, Division of 
Pulmonary Medicine, co-authored a paper, 
.. Chronic Necrotizing Pulmonary 
Aspergillosis- Approach to Management," 
which was published in the August, 1997 
issue of Chest. 
Alan B. Leahey, MD, Associate Chief, 
Division of Ophthalmology, John J. Shane, 
MD, Chairperson, Department of 
Pathology, Alan D. Listbaus, MD, 
Division of Ophthalmology, and MarkS. 
Trachtman, MD, Division of 
Ophthalmology, co-authored a paper, 
.. Molluscum Contagiosum Eyelid 
Lesions as the Initial Manifestation of 
Acquired Immunodeficiency Syndrome," 
which was published in Volume 1-24, No.8, 
August, 1997, oftheAmerican Journal of 
Ophthalmology. This is the first case in the 
literature known to date that describes these 
lid lesions as the initial manifestation of 
AIDS. 
Alexander M. Rosenau, DO, Department 
of Emergency Medicine, co-authored a 
paper, ••Paramedic Interpretation of 
Prehospital Lead- ll ST-Segments," which 
was published in the April-June 1997 issue 
of Prehospitlll and Disaster Medicine. 
This study was accomplished through the 
cooperation of the Emergency Medicine 
Residency ofthe Lehigh Valley. 
William E. Zajdel, DO, Department of 
Emergency Medicine, gave a presentation 
to the Upper Saucon-Township Board of 
Supervisors on the use of Automated 
External Defibrillators (AEDs). Following 
the presentation, the Board unanimously 
approved the purchase of the AEDs which 
will be used by the Police Department. Dr. 
Zajdel also volunteered to provide training 
to the township's 12 full-time officers in the 
use ofthe defibrillators. 
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Congratulations! 
Wayne E. Dubov, MD, Division of 
Physical Medicine/Rehabilitation, 
passed the certification exam as a 
certified Independent Medical 
Examiner which was given by the 
American Board of Independent 




Medical Grand Rounds 
Medical Grand Rounds are held every 
Tuesday from noon to 1 p.m., in the 
hospital's Auditorium at Cedar Crest 
& I-78. 
Topics to be discussed in October 
include: 
• October 7 - Cardiology 
• October 14 - Pulmonary 
• October 21 - General Internal 
Medicine 
• October 28 - Gastroenterology 
For more information, please contact 
Becky Sherman in the Department of 
Medicine at 402-8200. 
Department of Pediatrics 
Experience of Parents When Their 
Child is Diagnosed with Diabetes 
Mellitus will be presented on Friday, 
October 10, by Ellen Cooper, RN, 
MSN, CDE, Certified Diabetic 
Educator. 
Corrections in the Medical Record 
Regulatory guidelines indicate that all corrections 
in the medical record be made in the following ) 
manner: 
1. Draw a single line through the incorrect entry 
(without obliterating the entry), indicating 
"error,• "incorrect entry," etc. 
2. Date and initial the incorrect entry. 
3. If an entry is accidentally omitted, the entry is 
made after the last entry with an explanation 
of omission and reason it is out of order. 
Evaluation ofRespiratory 
Emergencies in Pediatrics will be 
presented on Friday, October 24, by 
Michael Weinstock, MD, Chairperson, 
Department of Emergency Medicine. 
Pediatric conferences begin at Noon 
and are held in the hospital's 
Auditorium at 17th & Chew. For 
more information, contact Kelli 
Ripperger in the Department of 
Pediatrics at 402-2540. 
Psychiatry Grand Rounds 
The Department of Psychiatry is 
pleased to announce that Margaret 
Caudill, MD, PhD, author of the best 
selling book, ''Managing Pain Before 
It Manages You," will be the featured 
speaker at the October Grand Rounds 
which will be held on October 16, 
beginning at noon, in the Auditorium 
at 17th & Chew. Dr. Caudill is the 
director of specialty and general 










Gavin C. Barr, Jr., MD 
L VPG-Emergency Medicine 
Lehigh Valley Hospital 
Cedar Crest & I-78 
P.O.Box689 
Allentown, PA 18105-1556 
(610) 402-8130 
FAX: (610) 402-1698 
Department of Emergency Medicine 
Division of Emergency Medicine 
Provisional Active 
Gary Bonfante, DO 
L VPG-Emergency Medicine 
Lehigh Valley Hospital 
Cedar Crest & I-78 
P.O.Box689 
Allentown, PA 18105-1556 
(610) 402-8130 
FAX: (610) 402-1698 
Department of Emergency Medicine 
Division of Emergency Medicine 
Provisional Active 
Anthony P. Buonanno, MD 
Bruce A. Ellsweig, MD, F AAFP 
1251 S. Cedar Crest Blvd. 
Suite 102A 
Allentown, PA 18103-6212 
(610) 776-0377 
FAX: (610) 776-0382 
Department of Family Practice 
Provisional Active 
Weldon E. Chafe, MD 
L VPG-Gynecologic Oncology 
Lehigh Valley Hospital 
Cedar Crest & I-78 
P.O.Box689 
Allentown, PA 18105-1556 
(610) 402-8334 
FAX: (610) 402-1667 
Department of Obstetrics and Gynecology 
Division of Gynecology · 
Section of Gynecologic Oncology 
Provisional Active 
Carla D. Chiapella, MD 
728 Delaware Avenue 
Bethlehem, PA 18015-1135 
(610) 882-9920 
Department of Surgery 
Division ofUrology 
(For Lithotripsy Only Privileges) 
Provisional Associate 
Randolph J. Cordle, MD 
L VPG-Emergency Medicine 
Lehigh Valley Hospital 
Cedar Crest & 1-78 
P.O.Box689 
Allentown, PA 18105-1556 
(610) 402-8130 
FAX: (610) 402-1698 
Department of Emergency Medicine 
Division of Emergency Medicine 
Provisional Active 
Monica C. Gavin, MD 
L VPG-Pediatrics 
Lehigh Valley Hospital 
17th&Chew 
P.O. Box 7017 
Allentown, PA 18105-7017 
(610) 402-2540 
FAX: (610) 402-9674 
Department of Pediatrics 
Division of General Pediatrics 
Provisional Active 
Olga Goldfarb, MD 
Martha A. Lusser, MD 
1251 S. Cedar Crest Blvd. 
Suite 301A 
Allentown, PA 18103-6247 
{610) 432-4114 
FAX: (610) 432-3939 
Department of Pediatrics 
Division ofNeurology 
Provisional Active 
Laurence P. Karper, MD 
L VPG-Psychiatry 
Fairgrounds Medical Center 
400 N. 17th Street 
Suite 207 
Allentown, PA 18104-5052 
(610) 402-9723 
FAX: (610) 776-7036 
Department of Psychiatry 
Division of Psychiatric Ambulatory 
Carel Adult Inpatient Psychiatry 
Provisional Active 
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Laura M. KeBey, MD 
L VPG-Pediatrics 
Lehigh Valley Hospital 
17th&Chew 
P.O. Box 7017 
Allentown, PA 18105-7017 
(610) 402-2540 
FAX: (610) 402-9674 
Department of Pediatrics 
Division of General Pediatrics 
Provisional Active 
Alfred P. Kennedy, Jr., MD 
L VPG-Pediatric Smgery 
(Chris Chang, MD) 
Allentown Medical Center 
401 N. l7th Street 
Suite 206 
Allentown, PA 18104-5050 
(610) 402-7999 
Department of Smgery 
Division of Pediatric Smgery 
Provisional Active 
Marian P. McDonald, MD 
General Smgical Associates 
1240 S. Cedar Crest Blvd. 
Suite 208 
Allentown, P A 18103-6218 
(610) 439-4055 
FAX: (610) 439-8650 
Department of Smgery 
Division of General Smgery 
Provisional Active 
Marion B. Rose, MD 
Children's Heart Center ofNortheastem 
PA 
(Louis W. Hansrote, MD) 
Allentown Medical Center 
401 N. 17th Street 
Suite 309 
Allentown, PA 18104-5050 
(610) 437-6687 
FAX: (610) 437-5232 
Department of Pediatrics 
Division of Cardiology 
Provisional Associate 
Jay S. Talsania, MD 
Orthopaedic Associates of Allentown 
1243 S. Cedar Crest Blvd. 
Suite 2500 
Allentown, PA 18103-7982 
(610) 433-6045 
FAX: (610) 433-3605 
Department of Smgery 
Division of Orthopedic Surgery 
Section of Ortho Trauma 
Provisional Active 
Steven J. Wassner, MD 
Milton S. Hershey Medical Center 
Department of Pediatrics 




Department of Pediatrics 
Division ofNephrology 
Provisional Associate 
Michael S. Weinstock, MD 
Chairperson, Department of Emergency 
Medicine 
L VPG-Emergency Medicine ) 
Lehigh Valley Hospital 
Cedar Crest & 1-78 
P.O.Box689 
Allentown, PA 18105-1556 
(610) 402-8130 
FAX: (610) 402-1698 
Department of Emergency Medicine 
Division of Emergency Medicine 
Provisional Active 
Robert E. Wilson, DO 
Allentown Anesthesia Associates, Inc. 
The Center for Pain Management 
1240 S. Cedar Crest Blvd. 
Suite 307 
Allentown, PA 18103-6218 
(610) 402-1756 -
FAX: (610) 402-1747 
Department of Anesthesiology 
Division of Pain Management 
Provisional Active 
(Continued on Page 15) 
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) Reappointment from LOA Appointment to Medical Staff 
Leadership Position 
Thomas R. Fitzsimons, MD 
Department of Radiology/Diagnostic Bruce A. Feldman, DO 
Medical Imaging Department of Medicine 
Division ofDiagnostic Radiology Division of Cardiology 
Active Position: Co-Medical Director of 4A 
(with Glenn M. Short, MD) 
Change of Status 
Mark C. Lester, MD 
Department of Surgery 
Division ofNeurological Surgery 
Sungji Chai, MD Position: Chief, Division of Neurological 
Department of Obstetrics and Gynecology Surgery 
Division of Primary Obstetrics and 
Gynecology Vincent R. Lucente, MD 
From Active to Affiliate Department of Obstetrics and Gynecology 
Howard S. Selden, DDS 
Position: Vice Chair, Academic Affairs 
Department of Dentistry Ernest Y. Normington n, MD 
Division of Endodontics Department of Obstetrics and Gynecology 
From Emeritus Affiliate to Honorary Position: Vice Chair, Medical Affairs 
Javad Sholehvar, MD Orion Rust, MD 
) 
Department of Surgery Department of Obstretrics and 
Division of Otolaryngology Gynecology 
From Affiliate to Honorary Division of Obstetrics 
Section of Clinical Inpatient Obstetrics 
Harry W. Stephens, MD Position: Chief of the Newly Formed 
Department of Surgery Section of Clinical Inpatient Obstetrics 
Division of Neurological Surgery 
Section ofNeuro Trauma David P. Steed, DPM 
From Emeritus Active/LOA to Honorary Department of Surgery 
Division of Orthopedic Surgery 
Robert Wasko, MD Section of Foot and Ankle Surgery 
Department of Surgery Position: Associate Chief, Section of 
Division of Urology Foot and Ankle Surgery 
From Active to Honorary 
Change of Address 
Change of Practice Anjam N. Bhatti, MD 
1611 Pond Road 
Sungji Chai, MD Suite 101 
Brighton Obstetrics and Gynecology Allentown, PA 18104-2256 
701 Ostrum Street (610) 366-2060 
Suite 403 FAX: (610) 366-8550 
Bethlehem, PA 18015-1184 
(610) 691-1141 
) .(Continued on Page 16) 
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Hanover Famlly Medical Group P. Denis Kuehner, DO 
) Ronald J. Buckley, MD (Orefield Medical Center) 
George L. Provost, MD Department of Family Practice 
1202 Hanover Avenue Provisional Affiliate 
Allentown, PA 18103-1998 
Steven J. Lawrence, MD 
Harry Z. Suprun, MD (Orthopaedic Associates of Allentown) 
2024 Lehigh Street Department of Surgery 
Allentown, PA 18103-4798 Division of Orthopedic Surgery 
(610) 402-8152 Section of Ortho Trauma 
FAX: (610) 402-1670 
David Lezinsky, DO 
Telephone Number Change (OB-GYN Care, Inc.) 
Department of Obstetrics and Gynecology 
Michael W. Kaufmann, MD Division of Primary Obstetrics and 
(610) 402-9723 Gynecology 
Active 
CWTord B. Schilke, MD 
Michael N. Pallone, MD (610) 402-9722 
(Milton S. Hershey Medical Center) 
Leave of Absence Department of Pediatrics 
Division of General Pediatrics 
John B. Samies, MD 
Provisional Limited Duty 
Department of Medicine 
Deborah A. Shalders, MD 
Division of Infectious Diseases Department of Family Practice ) Active 
Provisional Active 
B. David Vargas, MD 
Marcelle J. Shapiro, MD Department of Surgery 
(Medical Imaging of LV, PC) 
Division of Colon-Rectal Surgery 




Division ofDiagnostic Radiology 
Section of Cardiovascular!Interventi.onal 
Provisional Active 
Sarah M.Iriana, MD 
(Milton S. Hershey Medical Center) Constance B. Sutilla, MD 
Department of Pediatrics (Medical Imaging of LV, PC) 
Division of General Pediatrics Department of Radiology/Diagnostic 
Provisional Limited Duty Medical Imaging 
Division of Diagnostic Radiology 
KyleR. Kaulback, MD Section of Mammography 
(Emergency Care Associates of Provisional Active 
Allentown) 
Department of Emergency Medicine F. Geoffrey Toonder, MD 
Division of Emergency Medicine Department of Surgery 
Provisional Active Division of Cardio-Thoracic Surgery 
Active 
) 




(Continued from Page 16) 
Allied Health Professionals 
Appointments 




(Emergency Room- Dr. Lutz) 




(Sam Bub, MD, PC- Dr. Young) 




(Center for Women's Medicine - Dr. Klasko) 




(Lehigh Internal Medicine Assoc. - Dr. Zager) 




(Affinity- Dr. Pellosie) 




(Coordinated Health Systems- Dr. Dilorio) 




(Center for Women's Medicine - Dr. Klasko) 
Deborah L. Muhleisen, MS 
Associate Scientific 
Audiologist 
(Contracted Inpatient Services - Supervising 
Physician- Dr. Harwick) 




(Coordinated Health Systems- Dr. Busch) 




(The Heart Care Group, PC - Dr. Rossi) 
Additional Supervising 
Physicians 
Due to the merger of Cardiology Care 
Specialists and Cardiovascular Associates to 
form The Heart Care Group, PC, the 
following Allied Health Professionals will 
now report to all the physicians in the merged 
group: 
Allied Health Professionals 
Kim Fenstermacher, RN 
Kelly Plessl, RN 
Colleen Shaw, RN 
Pamela Stocker, RN 
Linda Duffy, RN 
Linda Gorman, RN 
Michelle Julian, RN 
Cath Leiby, RN 
Susan Nabhan, RN 
Physicians 
Donald J. Belmont, :MD 
Luis Constantin, MD 
Raymond A. Durkin, :MD 
Bruce A. Feldman, DO 
Hugh S. Gallagher, MD 
David B. Goldner, MD 
· Paul Gulotta, MD 
J. Patrick Kleaveland, MD 
Bryan W. Kluck, DO 
Norman H. Marcus, MD 
D. Lynn Morris, MD 
Stephen T. Olex, DO 
Robert J. Oriel, MD 
James A. Pantano, MD 
Gerald E. Pytlewski, DO 
Michael A. Rossi, MD 
James A. Sandberg, MD 
Melvin H. Schwartz, MD 
BruceJ.Silverberg,MD 
Steven L. Zelenkofske, MD 
(Continued on Page 18) 
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Change of Supervising 
Physician 




From Orthopaedic Associates of Allentown to 
Valley Sports & Arthritis Surgeons- Dr. 
Sussman) 
Resignations 




(Orthopaedic Associates of Allentown) 




(F. Geoffrey Toonder, MD, PC) 




(College Heights OBGYN Associates, PC) 




(The Heart Care Group, PC) 











1'HERAPEUTICS AT A GLANCE 
The following actions were taken at the July -August 1997 Therapeutics Committee Meeting- Howard Cook, R.Ph, BCNSP, FASHP, 
Rebecca Hockman, Pharm.D., Monica Yost, Phann.D .. 
CORRECTION 
In the May 1997 issue of the Medical Staff 
Progress Notes (V olum.e 9, Number 5), in the 
discussion of RezulinR (troglitazone), the 
statement appeared "It does not depend on 
insulin for its effect." The statement should read 
"It is dependent on the presence of insulin for its 
effect. Unlike sulfonylureas, troglitazone is not 
an insulin secretagogue." We regret any 
confusion with this information. 
HEPARIN THERAPY: 
DOSING AND MONITORING 
ISSUES 
As promised from the July Medical Staff 
.Progress Notes, this report updates issues in 
heparin dosing and monitoring as discussed by 
the L VH Heparin Therapeutics Subcommittee. 
The former Medical Staff Progress Notes 
discussed clarifications to be made on the L VH 
Weight-Based preprinted physicians order sheets. 
The current pre-printed Heparin Weight-Based 
Order Sheet now reflect the changes, which 
include the following: 
1) 
2) 
a statement for the use of TOTAL BODY WEIGHT 
in making dosing calculations 
with regard to heparin levels, the statement.was 
changed to "If heparin dose > 20 unitslkglhr, 
without attaining a therapeutic aPTI, obtain heparin 
level CJ yes o no." 
In order to improve awareness and appropriate 
use of the Weight-Based Order Sheet, Clinical 
Pharmacy Services developed a heparin dosing 
pocket card. The reverse side of the dosing card 
contains "helpful hints" regarding warfarin 
anticoagulation guidelines in dosing, monitoring 
and reversal of anticoagulant effect. The pocket 
) 
cards received Therapeutics Subcommittee and 
Committee approval, and after lamination, will 
be distributed to house staff and attendings. 
Additional subcommittee discussion focused on 
issues relating to heparin laboratory monitoring 
and validation of the aPTT. Annually, the LVH 
Laboratory must determine the "therapeutic 
aPTT range" that correlates with a heparin level 
of 0.2-0.4ulml. The Lab receives a specific 
reagent and lot number for use each year, and in 
accordance with National Proficiency Testing 
Standards, a heparin sensitivity curve is 
performed. Presently, the L VH aPTT range of 
4 7-7 6 seconds correlates with a heparin level of 
0.2-0.4ulml. This "therapeutic aPTT range" is 
subject to change annually, with the receipt of 
different reagent and lot. To assure the 
communication of these changes the 
subcommittee has requested that the Lab: 
1) report changes with a returned aPTI lab result in 
phamis 
2) send a one time e-mail to all physicians and 
pharmacists 
3) communicate change via an announcement- The 
Medical Staff Newsletter. 
The fmal topic of heparin therapy monitoring 
focused on concerns for appropriate use in 
heparin levels and the application of heparin 
levels in clinical practice. The majority of the 
medical literature describes therapeutic 
monitoring using aPTT or aPTT correlated with 
a heparin level of 0.2-0.4u/m.l, while only a 
small amount of literature describes monitoring 
using heparin levels. Heparin levels may be 
required in situations where the aPTT continues 
to be subtherapeutic despite appropriate dosing, 
or when required doses exceed 20u/kg/hr. 
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Subcommittee discussion evoked numerous 
potential patient-care complexities and 
interpatient variability issues that make specific 
guidelines development extremely difficult. The 
subcommittee elected to leave these situations to 
the clinical judgement of the prescnbing 
physician. 
A potential joint grand rounds for Medicine and 
Surgery is being investigated to aid in additional 
staff education for appropriate heparin dosing and 





The Therapeutics Committee approved an 
additional estrogen therapy option for L VH. 
Formulary: ClitnaraR-Estradiol Transdeimal 
System (Berlex Laboratories). Similar to 
EstradermR-Estradiol Transdermal biweekly 
patches, ClimaraR carries the FDA approved 
indications for the treatment of: 
1) moderate to severe vasomotor symptoms associated 
with the menopause 
2) vulval and vaginal atrophy 
3) hypoestroginism due to hypogonadism, castration or 
primary ovarian failure 
4) abnormal uterine bleeding due to hormonal 
imbalance and absence of organic pathology and only 
when associated with a hypoplastic or athrophic 
endometrium 
Likewise, adverse effects are as those 
experienced with other estrogen therapies, i.e. 
skin irritation at the application site, upper 
respiratory tract infection, headache, breast 
tenderness, breast pain, leukemia, and uterine 
bleeding. 
ClimaraR-Estrogen Transdermal System has 
undergone comparative trials only with oral 
estrogen and placebo. No additional efficacy or 
safety benefit has been demonstrated with 
ClimaraR, but potential advantages for use 
include: 1) once weekly application and 2) an 
additional treatment option for patients intolerant 
to other forms of estrogen hormonal replacement 
therapy. These advantages are offered at a cost 
equivalent to that of the EstradermR-Estradiol 
Transdermal Patch. ClimaraR weekly patches are 
available in two strengths designed to. release 
0.05mg/day and 0.1mg/day. 
ADVERSE DRUG REACTIONS 
SUMMARIZED 
639 Adverse Drug Reactions (ADR) were 
reported during the period 4/1196 through 
6/30/97. Pharmacists generated the majority of 
reports (73%). The distribution by reporter is 
shown in Table 1. The most common agents 
observed are listed in Table 2. 









































The Adverse Drug Reaction Probability ratings 
and severity classifications are shown in Tables 3 
and 4. Ninety seven ADR's were classified as 
severe. Among these, 7 deaths were reported. In 
all cases, the patients had several comorbidities 
which factored into this outcome. 
Table 3 - Probabilitv of Drug Related Problems 
Probabilities # Reoorts % ReQOrts 
Doubtful 16 2.5 
Possible 270 42.4 
Probable 353 55.1 
TOTAL 639 100.0 
) 
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. Table 4 - Adverse Reaction Severity 
) 










The most common severe adverse drug reactions 
are listed below in Table 5: 
Table 5 - Severe Adverse Drug Reactions by Drug Category 
Drug Category #Reports 
Cardiovascular Drugs 24 
Antibiotics/ Antifungals 14 
Abciximab (ReoPro) +/-heparin 5 
TPA (+I- heparin) 5 . 
CNS Drugs 18 













CHANGES TO ADR 
)REPORTING APPROVED 
Changes to the current Adverse Drug Reaction 
(ADR) reporting system, which improve the 
utilization of and accessibility to adverse drug 
reaction information, were approved by the 
Therapeutics Committee. Key elements to the 
"new" reporting system include: 
1) Patient Wallet Card- to be given to the patient upon 
the discovery of an adverse drug reaction, describing 
said reaction. 
2) Generation of letters to the patient and the 
physician(s) involved in the care of that patient, for 
all reactions classified as "allergic" and/or "severe." 
3) Distribution of Medic Alert Information to those 
patients listed in Number 2 above. 
The process as amended, will promote the 
distribution of accurate drug reaction information 
to all professionals responsible for the care of the 
patient. Housewide education of all patient care 
departments to the changes in the process will 
· occur upon availability of the wallet cards and 
)the new Adverse Drug Reaction Documentation 
Forms. 
NEW TREATMENT OPTION 
FOR CHF 
Carvedilol (CoregR, SmithKline Beechman)- a 
newly approved agent on LVH Formulary. It is 
FDA indicated as add on therapy for mild or 
moderate heart failure in patients taking digitalis, 
diuretics, and ACE inhibitors and for the 
management of essential hypertension. 
Carvedilol, competitively blocks B1,B2, and cx:1 
andrenoreceptors, and has vasodilating activity 
via alpha1 blockade. Carvedilols non-selective B 
and ex: 1, blockade counteract the increased 
sympathetic activity that may be associated with 
progressive myocardial damage in .heart failure. 
Carvedilol does lack intrinsic sympathomimetic 
activity and has not been shown to adversely 
effect serum lipid profiles. Currently, carvedilol 
is the only beta-blocking agent approved in the 
management of heart failure. Clinical efficacy 
with carvedilol suggests a combined reduction in 
mortality and hospitalizations when added to 
conventional therapy, slowed disease progression, 
and improved patient quality of life. 
The pharmacokinetics of carvedilol are 
characterized by rapid GI absorption, high 
plasma protein binding (98%) and extensive 
hepatic metabolism with biliary excretion. The 
primary cytochrome P450 enzymes responsible 
for metabolism include the CYP2D6 and 
CYP2CD isoenzymes. To date, significant drug 
interactions between CYP2D6 inhibitors 
(quinidine, fluoxetine, paroxetine, and 
propafenone) have not been studied, but 
extensive plasma protein binding and CYP450 
metabolism should lend caution·for many 
potential drug interactions. In addition to the 
above, patients requiring catecholamine depleting 
agents, clonidine, digoxin, calcium channel 
blockers, insulin and oral hypoglycemics may 
require additional monitoring. 
When initiating therapy patients should meet all 
of the following criteria: 
be stable on background medications 
consisting of diuretics, digoxin, and/or 
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ACE inlubitors 
not be hospitalized for heart failure 
not be in a fluid .overloaded state 
not be hypotensive 
The usual starting dose in heart failure is 
3.125mg BID for two weeks. If the initial dose is 
tolerated, the dose should be doubled every two 
weeks as tolerated to a maximum dose of 25mg 
BID ( < 85kg) and 50mg BID ( > 85kg). The 
recommended starting dose for hypertension is 
6.25mg BID titrated every two weeks as tolerated 
to a maximum daily dose of 50mg. Carvedilol 
should be taken with food and 2 hours prior to 
ACE inhibitors to reduce vasodilator side effects. 
The most common adverse effects are related to 
the vasodilating and B-blocking properties of 
carvedilol and include: orthostatic hypotension, 
dizziness, HA, dyspnea, bradycardia, fatigue, 
and worsening of CHF symptoms. Patients 
should be properly instructed on what to expect 
during the initial titration period. Carvedilol 
does not result in short-term symptomatic 
benefits. Patients may experience worsening of 
symptoms before long-term benefits are 
achieved. Adverse reactions are usually dose 
related and seen within the frrst week of therapy. 
The following adjustment of concomitant 
medications may also be necessary to minimize 
these side effects. 
Symptoms Initial Action Ifsvmotoms 
persist 
vasodilation( dizziness) decrease diuretic decrease 
or ACEI** carvedilol dose 
worsening CHF double diuretic decrease 
dose x.l-2 days carvedilol dose 
bradycardia, A V block decrease discontinue 
carvedilol dose carvedilol 
** Reduction in diuretic or ACEI dose is usually only needed 
temoorarily (3-7days). The prior dose should be resumed once 
the side effect is resolved. 
Contraindications to therapy include: 
NYHA class IV decompensated heart failure, 
bronchospastic disease, second or third degree 
A V block, SSS (unless permanently functioning 
pacemaker in place), cardiogenic shock (SBP < 
90 mmHg), bradycardia (HR < 60 bpm), and/or 
clinically manifest hepatic impairment. 
The Therapeutics Committee at L VH voted to 
add carvedilol to the formulary with further 
expectation to educate hospital staff members on 










Cedar Crest & I-78 
Post Office Box 689 
Allentown, Pennsylvania 18105-1556 
September 23, 1997 
The purpose of this letter is to clarify any misunderstandings that might have resulted from the September 16 
Morning Call article on Lehigh Valley Hospital's cardiac rehabilitation program. 
First and most importantly, the cardiac rehabilitation facility IS NOT CLOSING. The program's specially 
trained nurses and exercise physiologists will continue to provide high-quality services to help your patients 
recover from heart problems through individualized exercise prescription and education. This will assist your 
patients to return to their optimum physical and mental well-being and provide the necessary information for 
lifestyle modifications related to risk factor reduction. 
Inpatient cardiac rehabilitation will continue to be provided to patients throughout their stay in the hospital. 
Fallowing discharge, they will be encouraged to progress through the phase II outpatient medically monitored 
program. Your referral into the program is required. The focus of this program is on risk factor identification 
and lifestyle modification, in addition to individualized exercise progression. The duration of this program is 
up to 12 weeks, depending on individual insurance coverage. Upon completion of phase II, an intermediate 
program, phase III, is offered. The focus of phase III is to continue risk factor modification and endurance 
training with an emphasis on self-monitoring and progression toward independent exercise. The duration of 
this program is. up to 12 months. By the completion of phase III, your patient should have plateaued in 
exercise endurance and achieved stable risk factor management. After this, a long-term program for 
maintenance is encouraged. This may be a home program or a program at any health club. One facility we 
recommend is the Human Performance Center (HPC). The HPC has worked closely with us to, develop an 
alternative maintenance program for our graduates of phase III. We will assist your patient with this option, 
or any other option they choose, upon completion phase III. 
The outpatient components are currently taking place in the 1210 medical office building. We are pleased to 
announce that the outpatient program will be moving to a new, larger and more comfortable location across 
the street in the 1243 building on or around December 1, 1997. This provides more exercise space, improved 
environmental control for the cardiac patient, large locker rooms, educational consultation rooms and a body 
composition/screening room. We look forward to the improvements we will be able to offer your patients as a 
result of this move. 
We encourage you to continue to support both our inpatient and outpatient programs. You can do this by 
telling your patients about us and referring them into our programs. We have many patients that can attest to 
the excellent care they received while in our programs. Our greatest satisfaction is knowing that we made a 
difference in both the recovery from and prevention of heart disease. If you have any questions or concenis 
please contact Audrey Lichtenwalner, R.N., Director, Non-Invasive Cardiology at 610- 402-8855. 
tlwt':J.~~ 
Audrey Lichtenwalner, R.N. 
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Medical Staff Progress Notes 
is published monthly to 
inform the Lehigh Valley 
Hospital Medical Staff and 
employees of importaru 
issues concerning the 
Medical Staff. Articles 
should be submitted to Janet 
M. Seifert, Physician 
Relations, Lehigh Valley 
Hospital, Cedar Crest & 1·78, 
P.O. Box 689, Allentown, PA 
18105-1556, by the 15th of 
each month. If you have any 
questions about the 
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